Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week dose-ranging study of Fp Spiromax in persistent asthma
2010-023600-27Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fluticasone Spiromax in persistent asthma (6 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Primary efficacy endpoint. Started Nov 2011; status: completed.
02
Drugs
Fluticasone Spiromax
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2010-023600-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023600-27.